Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have...

Full description

Bibliographic Details
Main Authors: Karim Amrane, Luca Campedel, Coline Le Meur, Ronan Abgral, Dris Kharroubi, Jacques Cadranel
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Medicine
Subjects:
ROS1
ALK
therapeutic assessment
FDG-PET/CT
crizotinib
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.691253/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.691253/full

Similar Items